Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Case Report

Transperitoneal Laparoscopic Adrenalectomy for Metachronous Contralateral Adrenal Metastasis from Oligometastatic Renal Cell Cancer: Case Report and Review of the Literature

Author(s): Ercan Öğreden*, Ural Oguz, Erhan Demirelli, Doğan Sabri Tok, Safa Akyol, Hülya Öksüz and Serdar Aslan

Volume 20, 2024

Published on: 23 October, 2023

Article ID: e15734056244676 Pages: 6

DOI: 10.2174/0115734056244676231016094516

open_access

Abstract

Background: The definition of oligometastasis is still controversial. Cytoreductive nephrectomy and metastasectomy are important approaches in selected patients with oligometastasis for improving survival. We aimed to present our laparoscopic metastasectomy experience in a rare case of contralateral adrenal metastasis in an oligometastatic kidney tumor.

Case Report: A 52-year-old male patient was admitted to our clinic with the diagnosis of an incidental right renal mass. On contrast-enhanced abdominal CT revealed a mass reaching approximately 8 cm in diameter in the right kidney located in the middle pole. On contrast-enhanced thorax, CT showed a metastatic lesion in the left main bronchus bifurcation. The patient underwent an open radical nephrectomy with the diagnosis of an oligometastatic right renal mass. His pathology was reported as clear cell renal cell carcinoma (ccRCC). The patient was referred to the medical oncology clinic for immunotherapy. The metastatic lesion in the lung completely regressed in the follow-up of the patient who was started on Chek point inhibitors. However, he was referred to our clinic after an incidental metachronous mass was detected in the contralateral left adrenal in FDG PET/CT (SUVmax: 6.7) in 1st year. Dynamic contrast-enhanced MRI was performed to reevaluate and for mass characterization, and a 4 cm mass was observed in the left contralateral adrenal. Laparoscopic metastasectomy was performed for the left adrenal mass. No recurrence or adrenal insufficiency developed in the 6-month follow-up after discharge.

Conclusion: Transperitoneal adrenalectomy is a minimally invasive method that can be safely performed in metastatic adrenal masses. Although contralateral adrenal metastasis is rare in ccRCC, it should be kept in mind that adrenal metastasis may develop in the late period in patients with a history of renal cancer.

Keywords: Oligometastatic kidney cancer, Metachronous adrenal metastasis, Laparoscopic metastasectomy, Contrast-enhanced CT, Contrastenhanced MRI, Renal cell cancer.

[1]
Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol 2019; 75(1): 74-84.
[http://dx.doi.org/10.1016/j.eururo.2018.08.036] [PMID: 30243799]
[2]
Vasudev NS, Wilson M, Stewart GD, et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. BMJ Open 2020; 10(5): e035938.
[http://dx.doi.org/10.1136/bmjopen-2019-035938] [PMID: 32398335]
[3]
Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335(12): 865-75.
[http://dx.doi.org/10.1056/NEJM199609193351207] [PMID: 8778606]
[4]
Wang K, Wang J, Sun J, et al. Renal cell carcinoma with metachronous metastasis to the contralateral adrenal gland and urinary bladder: A case report. Oncol Lett 2015; 10(5): 2749-52.
[http://dx.doi.org/10.3892/ol.2015.3722] [PMID: 26722236]
[5]
Mikhail M, Chua KJ, Khizir L, Tabakin A, Singer EA. Role of metastasectomy in the management of renal cell carcinoma. Front Surg 2022; 9: 943604.
[http://dx.doi.org/10.3389/fsurg.2022.943604] [PMID: 35965871]
[6]
Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011; 8(6): 378-82.
[http://dx.doi.org/10.1038/nrclinonc.2011.44] [PMID: 21423255]
[7]
Culp SH, Tannir NM, Abel EJ, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 2010; 116(14): 3378-88.
[http://dx.doi.org/10.1002/cncr.25046] [PMID: 20564061]
[8]
Cozzoli A, Milano S, Cancarini G, Zanotelli T, Cunico SC. Surgery of lung metastases in renal cell carcinoma. Br J Urol 1995; 75(4): 445-7.
[http://dx.doi.org/10.1111/j.1464-410X.1995.tb07262.x] [PMID: 7788253]
[9]
Kollender Y, Bickels J, Price WM, et al. Metastatic renal cell carcinoma of bone: Indications and technique of surgical intervention. J Urol 2000; 164(5): 1505-8.
[http://dx.doi.org/10.1016/S0022-5347(05)67016-4] [PMID: 11025692]
[10]
Andoh H, Kurokawa T, Yasui O, Shibata S, Sato T. Resection of a solitary pancreatic metastasis from renal cell carcinoma with a gallbladder carcinoma: Report of a case. Surg Today 2004; 34(3): 272-5.
[http://dx.doi.org/10.1007/s00595-003-2680-6] [PMID: 14999544]
[11]
Balaban DV, Coman L, Marin FS, et al. Metastatic renal cell carcinoma to pancreas: Case series and review of the literature. Diagnostics 2023; 13(8): 1368.
[http://dx.doi.org/10.3390/diagnostics13081368] [PMID: 37189469]
[12]
Wang W, Li H, Li Y, Gao Z, Feng F, Lin C. Metachronous metastasis to contralateral retroperitoneal adipose tissue after radical nephrectomy: A case report and review of the literature. J Int Med Res 2019; 47(2): 1035-42.
[http://dx.doi.org/10.1177/0300060518816174] [PMID: 30556455]
[13]
Kessler OJ, Mukamel E, Weinstein R, Gayer E, Konichezky M, Servadio C. Metachronous renal cell carcinoma metastasis to the contralateral adrenal gland. Urology 1998; 51(4): 539-43.
[http://dx.doi.org/10.1016/S0090-4295(97)00698-5] [PMID: 9586603]
[14]
Antonelli A, Cozzoli A, Simeone C, et al. Surgical treatment of adrenal metastasis from renal cell carcinoma: A single-centre experience of 45 patients. BJU Int 2006; 97(3): 505-8.
[http://dx.doi.org/10.1111/j.1464-410X.2006.05934.x] [PMID: 16469016]
[15]
Ritchie AW, deKernion JB. The natural history and clinical features of renal carcinoma. Semin Nephrol 1987; 7(2): 131-9.
[PMID: 3306862]
[16]
Kumar R, Shamim SA, Shandal V, Sharma P, Gadodia A, Malhotra A. FDG PET/CT in detection of adrenal metastasis in patients with renal cell carcinoma. Clin Nucl Med 2011; 36(7): 513-7.
[http://dx.doi.org/10.1097/RLU.0b013e3182175435] [PMID: 21637050]
[17]
Chee C, Ravinthiran T, Cheng C. Laparoscopic adrenalectomy: experience with transabdominal and retroperitoneal approaches. Urology 1998; 51(1): 29-32.
[http://dx.doi.org/10.1016/S0090-4295(97)00468-8] [PMID: 9457284]
[18]
Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 2018; 379(5): 417-27.
[http://dx.doi.org/10.1056/NEJMoa1803675] [PMID: 29860937]
[19]
Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 2011; 117(13): 2873-82.
[http://dx.doi.org/10.1002/cncr.25836] [PMID: 21692048]
[20]
Petralia G, Roscigno M, Zigeuner R, et al. 450 Complete metastasectomy is an independent predictor of cancer-specific survival in patients with clinically metastatic renal cell carcinoma. Eur Urol Suppl 2010; 9(2): 162.
[http://dx.doi.org/10.1016/S1569-9056(10)60446-0]
[21]
Powles T, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022; 23(9): 1133-44.
[http://dx.doi.org/10.1016/S1470-2045(22)00487-9] [PMID: 36055304]
[22]
Imai T, Kikumori T, Ohiwa M, Mase T, Funahashi H. A case-controlled study of laparoscopic compared with open lateral adrenalectomy. Am J Surg 1999; 178(1): 50-3.
[http://dx.doi.org/10.1016/S0002-9610(99)00126-9] [PMID: 10456703]
[23]
Oba T, Sato N, Tamura T, Fujimoto K, Matsuyama A, Hirata K. Gallbladder metastasis of renal cell carcinoma presenting as a hypervascular polypoid lesion: Case report of two cases with immunohistochemical analysis. Surg Case Rep 2020; 6(1): 86.
[http://dx.doi.org/10.1186/s40792-020-00814-z] [PMID: 32347406]

© 2024 Bentham Science Publishers | Privacy Policy